Expression of PSTPIP1 in Renal Cell Carcinoma and Its Prognostic Value.

Renal clear cell carcinoma is the most common histological form of renal cancer, but targeted therapy is still lacking. PSTPIP1 is associated with multiple immune-related pathways and is higher expressed in tumors. Thus, the correlation of PSTPIP1 and ccRCC (clear cell renal cell carcinoma) was studied to evaluate the therapeutic potential of PSTPIP1 as a target for tackling ccRCC. The expression of PSTPIP1 mRNA in clear cell renal cell carcinoma (ccRCC) was analyzed using the Oncomine, TCGA, UALCAN, GSCA, and GEPIA databases and analysis tools. Immunohistochemistry (IHC) was utilized to detect PSTPIP1 protein in clinical samples, and the chi-square test, univariate analysis and multivariate analysis were utilized to verify the relationship between PSTPIP1 and ccRCC. Co-expressed genes and enriched pathways were obtained from the TCGA and GSEA (Gene Set Enrichment Analysis) database and analysis tool. A protein-protein interaction network was constructed to support mechanism analysis. PSTPIP1 expression was significantly elevated in ccRCC tissues compared with normal renal tissues. PSTPIP1 expression levels showed significant correlations with tumor size, TNM stage, and PD-L1 status. Overexpression of PSTPIP1 was closely associated with patient survival, with high PSTPIP1 expression serving as a prognostic factor for reduced overall survival in ccRCC patients. Our findings indicate that high expression of PSTPIP1 is a predictor of poor prognosis in ccRCC patients, suggesting this protein may represent a potential therapeutic target for ccRCC treatment.